The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The global pulmonary drug delivery market is projected to reach USD 52.37 billion by 2021 from USD 36.10 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market.
The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions.
Based on canister type, the market is segmented into plain canister and coated canister. The coated canister segment is expected to witness the highest growth during the forecast period due to various advantages such as robust profile for filling, avoiding crimping, and withstanding the pressure associated with the type of propellant (HFAs or CFCs), minimizing formulation and canister interactions and avoids deposition of HFA on the canister surface.
Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment is expected to witness the highest growth during the forecast period due to increasing prevalence of asthma across the globe.
Based on the end user, the market is segmented into hospitals & clinics and homecare settings. Homecare settings is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to technological advancements in pulmonary drug delivery devices that enable their use in the home care settings. Digital inhalers allow patients to maintain medical records and dosage of the drug administered; this also enable patients to share this record with physicians.
Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing aging population, increasing adoption of an unhealthy lifestyle, increasing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region. Presently, North America is expected to dominate the market. This is due to increasing technological developments, increasing prevalence of chronic respiratory and supportive reimbursement policies in the form of Medicare and Medicaid
The key players in the pulmonary drug delivery market focus on various organic and inorganic growth strategies such as agreements, collaborations, expansions, product launches & approvals, and partnerships.
The key players in this market are Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).
Apart from the comprehensive geographical analysis, product analysis, and market sizing the report also provides a competitive landscape that covers the growth strategies adopted by industry players in the last three years. In addition, the company profiles comprise basic views on the key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, change in strategic approach, and R&D investments for innovations in products and technologies, and levels of output to remain successful.
The report defines, describes, and forecasts the pulmonary drug delivery market on the basis of formulations, canister type, application, end user, and regions. It provides detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges). The study tracks and analyzes competitive developments such as acquisitions, product developments, and expansions in the pulmonary drug delivery market across four main regions, namely, North America, Asia, Europe, and the Rest of the World (RoW).
Reasons To Buy the report:
The report on “Pulmonary Drug Delivery” provides quantitative information for clients seeking market size information on various segments of the pulmonary drug delivery market.
This report also provides access to the quantitative data on pulmonary drug delivery market. This report covers –
- Current and forecast assessment of the global pulmonary drug delivery market
- Country-wise assessment of each of the segments
- Global market share analysis of major segments of the pulmonary drug delivery market
- Adoption trends of pulmonary drug delivery in major geographic segments
- Five-year coverage of strategic developments of top players in the pulmonary drug delivery market
- Product portfolio mapping of leading players in the pulmonary drug delivery market